A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)

被引：0

作者：

O'Cearbhaill, Roisin ^{[1
]}

Sill, Michael ^{[2
]}

Duong, Hoa ^{[3
]}

Waggoner, Steven ^{[4
]}

Grisham, Rachel ^{[1
]}

Backes, Floor ^{[5
]}

Mannel, Robert ^{[6
]}

Tanyi, Janos ^{[7
]}

Powell, Matthew ^{[8
]}

Mathews, Cara ^{[9
]}

Ghamande, Sharad ^{[10
]}

Mcnally, Leah ^{[11
]}

Olawaiye, Alexander ^{[12
]}

Bender, David ^{[13
]}

Duska, Linda ^{[14
]}

Lankes, Heather ^{[15
]}

Zamarin, Dmitriy ^{[16
]}

Schilder, Russell ^{[17
]}

Bookman, Michael ^{[18
]}

Aghajanian, Carol ^{[1
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] NRG Oncol Stat & Data Management Ctr, Biostat & Bioinformat Dept, Buffalo, NY USA

[3] Kaiser Permanente Sacramento, Hematol Oncol, Sacramento, CA USA

[4] CWRU Case Comprehens Canc Ctr, Gynecol Oncol, Cleveland, OH USA

[5] Ohio State Univ, Comprehens Canc Ctr, Gynecol Oncol, Columbus, OH USA

[6] Univ Oklahoma, Hlth Sci Ctr, Obstet & Gynecol, Oklahoma City, OK USA

[7] Univ Penn, Abramson Canc Ctr, Obstet & Gynecol, Philadelphia, PA 19104 USA

[8] Washington Univ, Gynecol Oncol, St Louis, MO 63110 USA

[9] Women & Infants Hosp Rhode Isl, Obstet & Gynecol, Providence, RI USA

[10] Georgia Cares Minor Underserved NCORP, Gynecol Oncol, Augusta, GA USA

[11] Duke Canc Inst, Gynecol Oncol, Durham, NC USA

[12] UPMC Hillman Canc Ctr, Gynecol Oncol, Pittsburgh, PA USA

[13] Univ Iowa, Obstet & Gynecol, Iowa City, IA USA

[14] Univ Virginia, Gynecol Oncol, Canc Ctr, Charlottesville, VA USA

[15] NRG Oncol Biospecimen Bank Columbus, Translat Sci Operat, Columbus, OH USA

[16] Icahn Sch Med Mt Sinai, Hematol Oncol, New York, NY 10029 USA

[17] Thomas Jefferson Univ, Gynecol Med Oncol, Philadelphia, PA 19107 USA

[18] Kaiser Permanente Northern Calif, Gynecol Oncol, San Francisco, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO005LBA

引用

页码：A4 / A4

页数：1

共 50 条

[31] Avelumab (MSB0010718C; anti-PD-Li) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.
Pujade-Lourraine, Eric
Colombo, Nicoletta
Disis, Mary L.
Fujiwara, Keiichi
Ledermann, Jonathan A.
Mirza, Mansoor Raza
Richardson, Gary Edward
Beck, J. Thaddeus
Gaillard, Stephanie
Haney, Patricia
Shnaidman, Michael
Morozov, Alexei
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[32] Randomized phase II study of the PDGFR antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
McGuire, William P.
Penson, Richard T.
Gore, Martin
Herraez, Antonio Casado
Peterson, Patrick
Shahir, Ashwin
Ilaria, Robert, Jr.
BMC CANCER, 2018, 18
[33] A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
Wu, Lingying
Wang, Jing
Wang, Li
Lu, Weiguo
Wang, Ke
Lin, An
Li, Ning
Li, Li
Su, Ning
Xie, Shuang
Jiang, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
William P. McGuire
Richard T. Penson
Martin Gore
Antonio Casado Herraez
Patrick Peterson
Ashwin Shahir
Robert Ilaria
BMC Cancer, 18
[35] Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
Kikuchi, Y., Sr.
Kouta, H.
Kikuchi, R.
Takano, M.
Kita, T.
Kudoh, K.
Aoki, D.
Sugiyama, T.
Isonishi, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[36] Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Gaillard, Stephanie
Oaknin, Ana
Ray-Coquard, Isabelle
Vergote, Ignace
Scambia, Giovanni
Colombo, Nicoletta
Fernandez, Cristian
Alfaro, Vicente
Kahatt, Carmen
Nieto, Antonio
Zeaiter, Ali
Aracil, Miguel
Vidal, Laura
Pardo-Burdalo, Beatriz
Papai, Zsuzsanna
Kristeleit, Rebecca
O'Malley, David M.
Benjamin, Ivor
Pautier, Patricia
Lorusso, Domenica
GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 237 - 245
[37] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
Monk, B. J.
Herzog, T. J.
Kaye, S. B.
Krasner, C. N.
Vermorken, J. B.
Muggia, F.
Pujade-Lourraine, E.
Zintl, P.
Parekh, T. V.
Poveda, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[38] Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
Perez-Fidalgo, J. A.
Cortes, A.
Guerra, E.
Garcia, Y.
Iglesias, M.
Sarmiento, U. Bohn
Garcia, E. Calvo
Sanchez, L. Manso
Santaballa, A.
Oaknin, A.
Redondo, A.
Rubio, M. J.
Gonzalez-Martin, A.
ESMO OPEN, 2021, 6 (04)
[39] Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
Matulonis, U. A.
Barry, W.
Penson, R. T.
Konstantinopoulos, P. A.
Luo, W.
Hoffman, M. A.
Horowitz, N. S.
Farooq, S.
Dizon, D. S.
Stover, E.
Wright, A. A.
Campos, S. M.
Krasner, C.
Liu, J. F.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 24
[40] CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
Gaillard, Stephanie
Ghamande, Sharad A.
Pardo, Beatriz
Lorusso, Domenica
Vergote, Ignace
Papai, Zsuzsanna
O'Malley, D.
Kristeleit, Rebecca Sophie
Redondo, Andres
Timcheva, Constanta
Fernandez, Cristian
Nieto, Antonio
Soto-Matos, Arturo
Moss, Keren Rachel
Baumann, Klaus H.
Ray-Coquard, Isabelle
Oaknin, Ana
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →